DOP2016000152A - Quinazolin-thf-aminas como inhibidores de pde1. - Google Patents
Quinazolin-thf-aminas como inhibidores de pde1.Info
- Publication number
- DOP2016000152A DOP2016000152A DO2016000152A DO2016000152A DOP2016000152A DO P2016000152 A DOP2016000152 A DO P2016000152A DO 2016000152 A DO2016000152 A DO 2016000152A DO 2016000152 A DO2016000152 A DO 2016000152A DO P2016000152 A DOP2016000152 A DO P2016000152A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- aminas
- quinazolin
- thf
- pde1 inhibitors
- pde1
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA QUINAZOLIN-THF-AMINAS COMO INHIBIDORES DE PDE1 Y SU USO COMO UN MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y TRASTORNOS PSIQUIÁTRICOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300707 | 2013-12-19 | ||
| DKPA201400249 | 2014-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000152A true DOP2016000152A (es) | 2016-09-30 |
Family
ID=52350066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000152A DOP2016000152A (es) | 2013-12-19 | 2016-06-17 | Quinazolin-thf-aminas como inhibidores de pde1. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20150175584A1 (es) |
| EP (1) | EP3083607B1 (es) |
| JP (1) | JP6419832B2 (es) |
| KR (1) | KR20160098269A (es) |
| CN (1) | CN105829300B (es) |
| AP (1) | AP2016009293A0 (es) |
| AU (1) | AU2014368601B2 (es) |
| BR (1) | BR112016013946A8 (es) |
| CA (1) | CA2933299A1 (es) |
| CL (1) | CL2016001488A1 (es) |
| CR (1) | CR20160282A (es) |
| DO (1) | DOP2016000152A (es) |
| EA (1) | EA201691108A1 (es) |
| EC (1) | ECSP16061208A (es) |
| ES (1) | ES2728079T3 (es) |
| GE (1) | GEP201706764B (es) |
| IL (1) | IL246230A0 (es) |
| MX (1) | MX2016007945A (es) |
| PE (1) | PE20160855A1 (es) |
| PH (1) | PH12016501173A1 (es) |
| RU (1) | RU2016125315A (es) |
| SG (1) | SG11201604936TA (es) |
| SV (1) | SV2016005220A (es) |
| TN (1) | TN2016000239A1 (es) |
| TW (1) | TW201609713A (es) |
| WO (1) | WO2015091805A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609713A (zh) * | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| RS60017B1 (sr) | 2014-04-04 | 2020-04-30 | H Lundbeck As | Halogenovani kvinazolin-thf-amini kao pde1 inhibitori |
| TWI729109B (zh) * | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| AU2019275453B2 (en) | 2018-05-25 | 2023-12-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575916B1 (en) * | 2001-08-31 | 2013-05-22 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| ZA200507228B (en) * | 2003-04-01 | 2007-03-28 | Applied Research Systems | Inhibitors of phosphodiesterases in infertility |
| CA2565037A1 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| AU2006279548A1 (en) * | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| WO2007096743A1 (en) * | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| EP2279009A4 (en) * | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| US9468637B2 (en) * | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2011036074A1 (en) * | 2009-09-24 | 2011-03-31 | Basf Se | Aminoquinazoline compounds for combating invertebrate pests |
| TW201609713A (zh) | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
-
2014
- 2014-12-01 TW TW103141539A patent/TW201609713A/zh unknown
- 2014-12-18 AP AP2016009293A patent/AP2016009293A0/en unknown
- 2014-12-18 EP EP14827431.9A patent/EP3083607B1/en active Active
- 2014-12-18 CN CN201480068495.XA patent/CN105829300B/zh not_active Expired - Fee Related
- 2014-12-18 SG SG11201604936TA patent/SG11201604936TA/en unknown
- 2014-12-18 US US14/574,425 patent/US20150175584A1/en not_active Abandoned
- 2014-12-18 US US15/105,647 patent/US9701665B2/en not_active Expired - Fee Related
- 2014-12-18 PE PE2016000825A patent/PE20160855A1/es not_active Application Discontinuation
- 2014-12-18 MX MX2016007945A patent/MX2016007945A/es unknown
- 2014-12-18 JP JP2016541407A patent/JP6419832B2/ja not_active Expired - Fee Related
- 2014-12-18 WO PCT/EP2014/078475 patent/WO2015091805A1/en not_active Ceased
- 2014-12-18 CR CR20160282A patent/CR20160282A/es unknown
- 2014-12-18 BR BR112016013946A patent/BR112016013946A8/pt not_active IP Right Cessation
- 2014-12-18 AU AU2014368601A patent/AU2014368601B2/en not_active Expired - Fee Related
- 2014-12-18 KR KR1020167016258A patent/KR20160098269A/ko not_active Withdrawn
- 2014-12-18 ES ES14827431T patent/ES2728079T3/es active Active
- 2014-12-18 RU RU2016125315A patent/RU2016125315A/ru unknown
- 2014-12-18 EA EA201691108A patent/EA201691108A1/ru unknown
- 2014-12-18 GE GEAP201414180A patent/GEP201706764B/en unknown
- 2014-12-18 TN TN2016000239A patent/TN2016000239A1/en unknown
- 2014-12-18 CA CA2933299A patent/CA2933299A1/en not_active Abandoned
-
2016
- 2016-06-14 CL CL2016001488A patent/CL2016001488A1/es unknown
- 2016-06-15 SV SV2016005220A patent/SV2016005220A/es unknown
- 2016-06-15 IL IL246230A patent/IL246230A0/en not_active IP Right Cessation
- 2016-06-16 PH PH12016501173A patent/PH12016501173A1/en unknown
- 2016-06-17 DO DO2016000152A patent/DOP2016000152A/es unknown
- 2016-07-18 EC ECIEPI201661208A patent/ECSP16061208A/es unknown
-
2017
- 2017-06-05 US US15/614,104 patent/US10030007B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| MX2018015734A (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1. | |
| DOP2016000152A (es) | Quinazolin-thf-aminas como inhibidores de pde1. | |
| ECSP16082599A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 |